Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Danuglipron (PF-06882961) in Chinese Adults with T2DM
NCT04889157Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Danuglipron with Placebo (2 arms). Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to 24 Hours, Maximum Observed Concentration at Day 1 and 1 more. Started Jul 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04889157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889157.